Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Trolnitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trolnitrate SCHEMBL6390411 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MEN1CYP2C9ALOX15CYP2C19 | |
| Trolnitrate SCHEMBL17311175 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL22588490 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL1718077 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL22397745 | 0.98 | ALDH1A1 (0.33) | ALDH1A1MMP2MMP9 | |
| Trolnitrate SCHEMBL10597128 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL9249444 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL11423298 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL10606948 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| Trolnitrate SCHEMBL22829339 | 0.96 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070479-A | Ultrasonic indicating device and method for monitoring ultrasonic treatment | JP实验室股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-119968448-A | Cationically curable adhesives with retained strength indication | 德莎欧洲股份公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119410282-A | Detection adhesive tape and preparation method and application thereof | 三一红象电池有限公司 | 2025-02-11 | — | — | CN | claimed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| CN-116465878-A | Array material and method for detecting VOCs component in gas | 重庆大学 | 2023-07-21 | — | — | CN | claimed |
| CN-113917005-B | Method for detecting content of intermediate amine yellow in food | 中国肉类食品综合研究中心 | 2023-06-06 | — | — | CN | claimed |
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-03-23 | — | — | US | claimed |
| US-11324748-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-05-10 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-5302641-A | Ammonium or amine phosphate or phosphonate, resin of substituted oligomeric melamine and aldehyde, thermoplastic or elastomeric polymer | Ministero Dell `Universita` e Della Ricerca Scientifica e Tecnologica (IT) | 1994-04-12 | — | — | US | claimed |
| WO-1994003421-A2 | ESTERS AND COMBINATIONS OF AN ORGANIC NITRATE AND A SALICYLATE | CAL INTERNATIONAL LIMITED (IE) | 1994-02-17 | — | — | WO | claimed |
| US-5232705-A | Hypotensive agents. vasodilators | ALZA CORPORATION (US) | 1993-08-03 | — | — | US | claimed |
| EP-0546038-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY. | ALZA CORP (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0538335-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY. | ALZA CORP (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992004011-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORPORATION (US) | 1992-03-19 | — | — | WO | claimed |
| WO-1992000729-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
| EP-0158128-B1 | PROCESS FOR PRODUCING CATHODICALLY DEPOSITABLE ELECTRO-DIPPING PAINT BINDERS | Vianova Kunstharz Aktiengesellschaft (AT) | 1987-11-25 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0014026-B1 | PAPER CONTAINING PARTIALLY CURED AMINO/ALDEHYDE FIBRES AND PROCESS FOR MAKING IT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | ALDH1A1 1929/4885MEN1 3475/4885CYP2C9 3710/4885 |
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | ALDH1A1 2053/4885MEN1 4405/4885CYP2C9 2666/4885 |
| US-11324748-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | ALDH1A1 1929/4885MEN1 3475/4885CYP2C9 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.